Lilly's Oral GLP-1 Foundayo Cuts Sleep Apnea Events in a One-Year Study
- In a one-year trial in patients not using PAP therapy, Foundayo cut the apnea-hypopnea index by 17.8 events per hour versus 4.5 on placebo.
- About 28% of treated patients reached remission or mild disease, against 13% on placebo.
- Data were shown at the AHA meeting and published in JAMA; STAT notes the pill does not look as effective as injectable Zepbound.
💡 Points Based on public reports
Zepbound already holds the sleep apnea label, so the pill's role is breadth: a convenient option for the many apnea patients who also carry obesity, and a way to extend the franchise without needles or cold chain. Expect payers to ask whether a weaker oral effect justifies a new indication, and for Lilly to pitch it as a step-down or maintenance choice.
STAT+: Eli Lilly's GLP-1 pill Foundayo helped alleviate sleep apnea in studies ↗